Open Access

Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer

  • Authors:
    • Wenjie Dong
    • Na Li
    • Xiufeng Pei
    • Xinai Wu
  • View Affiliations

  • Published online on: January 26, 2018     https://doi.org/10.3892/ol.2018.7881
  • Pages: 4207-4214
  • Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Dual-specificity phosphatase-2 (DUSP2), a negative regulator of extracellular‑regulated kinase activity, has been identified as an important kinase with emerging roles in cancer. However, the clinical significance of DUSP2 in colorectal cancer (CRC) remains to be fully elucidated. In the present study, the expression of DUSP2 was investigated using immunohistochemistry in 96 patients with CRC. Cell viability was estimated using a cell counting kit‑8 assay, and cell apoptosis by flow cytometry. The relationship between DUSP2 expression and patient characteristics, including overall survival, were studied retrospectively in these patients. It was found that DUSP2 was differentially expressed between left‑sided colon carcinoma (LSCC) and right‑sided colon carcinoma (RSCC). It was also found that decreased expression of DUSP2 was correlated with significantly shorter overall survival (P=0.001) and short distant-metastasis-free survival (P=0.002). In univariate comparisons, the decreased expression of DUSP2 was found to be an independent risk factor for poor survival rate (HR 3.55, CI 1.092‑9.896; P=0.002). It was also found that the enforced overexpression of DUSP2 sensitized CRC cells to cetuximab. In conclusion, the findings demonstrated that DUSP2 was differentially expressed between RSCC and LSCC, and that the overexpression of DUSP2 increased the inhibitory effect of cetuximab in CRC, suggesting that DUSP2 may be a novel biomarker and therapeutic target in CRC therapy.

References

1 

Bermudez O, Pages G and Gimond C: The dual-specificity MAP kinase phosphatases: Critical roles in development and cancer. Am J Physiol Cell Physiol. 299:C189–C202. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Wei W, Jiao Y, Postlethwaite A, Stuart JM, Wang Y, Sun D and Gu W: Dual-specificity phosphatases 2: Surprising positive effect at the molecular level and a potential biomarker of diseases. Genes Immun. 14:1–6. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Hamamura K, Nishimura A, Chen A, Takigawa S, Sudo A and Yokota H: Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. Cellular signalling. 27:828–835. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Perander M, Al-Mahdi R, Jensen TC, Nunn JA, Kildalsen H, Johansen B, Gabrielsen M, Keyse SM and Seternes OM: Regulation of atypical MAP kinases ERK3 and ERK4 by the phosphatase DUSP2. Sci Rep. 7:434712017. View Article : Google Scholar : PubMed/NCBI

5 

Yin Y, Liu YX, Jin YJ, Hall EJ and Barrett JC: PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature. 422:527–531. 2003. View Article : Google Scholar : PubMed/NCBI

6 

Haag T, Richter AM, Schneider MB, Jimenez AP and Dammann RH: The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms. BMC Cancer. 16:492016. View Article : Google Scholar : PubMed/NCBI

7 

Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF, Lai YY, Lin SC and Tsai SJ: Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest. 121:1905–1916. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Lee YH, Morrison BL and Bottaro DP: Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem. 289:20448–20461. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Karakashev SV and Reginato MJ: Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget. 6:1967–1980. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Hou PC, Li YH, Lin SC, Lin SC, Lee JC, Lin BW, Liou JP, Chang JY, Kuo CC, Liu YM, et al: Hypoxia-Induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. Cancer Res. 77:4305–4316. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Lin SC, Hsiao KY, Chang N, Hou PC and Tsai SJ: Loss of dual-specificity phosphatase-2 promotes angiogenesis and metastasis via up-regulation of interleukin-8 in colon cancer. J Pathol. 241:638–648. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG and Reich R: The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol. 93:517–523. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Zhu W, Huang L, Xu X, Qian H and Xu W: Anti-proliferation effect of BMI-1 in U937 cells with siRNA. Int J Mol Med. 25:889–895. 2010.PubMed/NCBI

14 

Wang XF, Zhao YB, Wu Q, Sun ZH and Li HJ: Triptolide induces apoptosis in endometrial cancer via a p53 independent mitochondrial pathway. Mol Med Rep. 9:39–44. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J and Berra E: HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer. 120:1451–1458. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Tashiro E, Henmi S, Odake H, Ino S and Imoto M: Involvement of the MEK/ERK pathway in EGF-induced E-cadherin down-regulation. Biochem Biophys Res Commun. 477:801–806. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Boeckx C, Op de Beeck K, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P, Vermorken JB, Peeters M, et al: Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. Cancer Lett. 354:365–377. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Chen Y, Huang Y, Hou P, Zhang Z, Zhang Y, Wang W, Sun G, Xu L, Zhou J, Bai J and Zheng J: ING4 suppresses tumor angiogenesis and functions as a prognostic marker in human colorectal cancer. Oncotarget. 7:79017–79031. 2016.PubMed/NCBI

19 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Zhang X, Song Y, Song N, Zhang Y, Zhang L, Wang Y, Wang Z, Qu X and Liu Y: RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src. Onco Targets Ther. 10:73–83. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, et al: Adjuvant FOLFOX +/−cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. Ann Oncol. 28:824–830. 2017.PubMed/NCBI

22 

Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R and Menendez JA: Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget. 7:82185–82199. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, Luo HY, Zhang DS, Jin Y, Wang FH, et al: Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 34:384–393. 2015. View Article : Google Scholar : PubMed/NCBI

24 

Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, et al: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 51:1405–1414. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, et al: Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 21:988–994. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev. 17:79–92. 2017. View Article : Google Scholar

27 

Zhu H, Wu TC, Chen WQ, Zhou LJ, Wu Y, Zeng L and Pei HP: Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis. Oncol Lett. 6:353–358. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Joo D, Woo JS, Cho KH, Han SH, Min TS, Yang DC and Yun CH: Biphasic activation of extracellular signal-regulated kinase (ERK)1/2 in epidermal growth factor (EGF)-stimulated SW480 colorectal cancer cells. BMB Rep. 49:220–225. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Dong, W., Li, N., Pei, X., & Wu, X. (2018). Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer. Oncology Letters, 15, 4207-4214. https://doi.org/10.3892/ol.2018.7881
MLA
Dong, W., Li, N., Pei, X., Wu, X."Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer". Oncology Letters 15.4 (2018): 4207-4214.
Chicago
Dong, W., Li, N., Pei, X., Wu, X."Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer". Oncology Letters 15, no. 4 (2018): 4207-4214. https://doi.org/10.3892/ol.2018.7881